Resveratrol in COVID19

Phase 3

Recruiting

• Conditions: COVID19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20200112046089N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 July 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Polymerase chain reaction (PCR) confirmed infection with SARS CoV2
Lung involvement confirmed with chest imaging
Hospitalized with: Fever (axillar or oral temperature = 38.0 °centigrade(C) or =38.6°centigrade tympanic or rectal) or Respiratory rate >24/min Or Cough
Less than 8 days since illness onset
Willingness of study participant to accept random assignment to any treatment arm
Acceptance of non-participation in another study before the 28th day of the study

Exclusion Criteria

Autoimmune diseases (lupus, MS, etc.)
Hepatic failure
Hepatit B and C
pregnant and lactating women

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Recovery time. Timepoint: Duration of treatment. Method of measurement: Evaluation of clinical symptoms.;Repiratory signs. Timepoint: daily. Method of measurement: clinical evaluation and questionnaire.;Pulmonary Condition. Timepoint: Before intervention and 14 days after intervention. Method of measurement: CT scan.

Secondary Outcome Measures

Name	Time	Method
Blood oxygen saturation percentage. Timepoint: Before and 14 days after starting treatment. Method of measurement: Pulse oximeter.;C-Reactive Protein (CRP). Timepoint: Before and fourteen days after starting treatment. Method of measurement: ?ELISA (enzyme-linked immunosorbent assay).;IL6. Timepoint: Before and 14 days after starting treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).;IL1. Timepoint: Before and 14 days after starting treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).;CBC. Timepoint: Before and 14 days after starting treatment. Method of measurement: Cell Counter.